Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Coherus Oncology (CHRS) EBITDA (2016 - 2025)

Historic EBITDA for Coherus Oncology (CHRS) over the last 13 years, with Q3 2025 value amounting to -$44.3 million.

  • Coherus Oncology's EBITDA rose 538.46% to -$44.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$92.7 million, marking a year-over-year increase of 5848.44%. This contributed to the annual value of -$111.7 million for FY2024, which is 4504.55% up from last year.
  • Latest data reveals that Coherus Oncology reported EBITDA of -$44.3 million as of Q3 2025, which was up 538.46% from -$45.5 million recorded in Q2 2025.
  • In the past 5 years, Coherus Oncology's EBITDA registered a high of $42.6 million during Q4 2024, and its lowest value of -$167.4 million during Q1 2021.
  • Its 5-year average for EBITDA is -$51.1 million, with a median of -$45.4 million in 2025.
  • As far as peak fluctuations go, Coherus Oncology's EBITDA plummeted by 50951.36% in 2021, and later skyrocketed by 16182.72% in 2024.
  • Over the past 5 years, Coherus Oncology's EBITDA (Quarter) stood at -$39.5 million in 2021, then plummeted by 30.21% to -$51.5 million in 2022, then plummeted by 33.81% to -$68.9 million in 2023, then surged by 161.83% to $42.6 million in 2024, then tumbled by 204.06% to -$44.3 million in 2025.
  • Its EBITDA stands at -$44.3 million for Q3 2025, versus -$45.5 million for Q2 2025 and -$45.4 million for Q1 2025.